

## Semaglutide (Wegovy®)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

### POS Abbreviations

<b>AL</b> – Age Limit	<b>DS</b> – Maximum Days' Supply Allowed	<b>PU</b> – Prior Use of Other Medication is Required
<b>BH</b> – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	<b>DT</b> – Duration of Therapy Limit	<b>QL</b> – Quantity Limit
<b>BY</b> – Diagnosis Codes Bypass Some Requirements	<b>DX</b> – Diagnosis Code Requirement	<b>RX</b> – Specific Prescription Requirement
<b>CL</b> – Additional Clinical Information is Required	<b>ER</b> – Early Refill	<b>TD</b> – Therapeutic Duplication
<b>CU</b> – Concurrent Use with Other Medication is Restricted	<b>MD</b> – Maximum Dose Limit	<b>YQ</b> – Yearly Quantity Limit
<b>DD</b> – Drug-Drug Interaction	<b>MME</b> – Maximum Morphine Milligram Equivalent is Restricted	

## Semaglutide (Wegovy®)

POS Edits
<p><b>CL</b> – Additional clinical information (age, diagnosis, etc.) is required for this agent.</p>
<p><b>QL</b> – <a href="#">Wegovy® injection</a> is limited to a quantity of 4 syringes (1 carton) every 28 days. <a href="#">Wegovy® tablets are limited to a quantity of 1 tablet per day.</a> <i>Requests to override the Quantity Limit for this agent should follow <a href="#">THIS CRITERIA</a>.</i></p>
<p><b>TD</b> – This agent is monitored at the pharmacy POS for duplication of therapy with other GLP-1 receptor agonists or DPP-4 inhibitors. <i>Requests to override the Therapeutic Duplication for this agent should follow <a href="#">THIS CRITERIA</a>.</i></p>

Revision / Date	Implementation Date
Created POS Document / May 2024	October 2024
<a href="#">Added tablet formulation / January 2026</a>	<a href="#">March 2026</a>